| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Deramciclane is a novel anxiolytic drug with a high affinity for 5-HT2A/2C receptors. Deramcicane's interaction with the serotonin 5-HT2C receptor was further investigated utilizing receptor phosphoinositide hydrolysis assay and receptor autoradiography. Deramciclane inhibits 5-HT2C receptor-mediated 5-HT-induced phosphoinositide hydrolysis with an IC50 of 168 nM. Deramcicane also lowers basal phosphoinositide hydrolysis in the choroid plexus physiological system by up to 33% (EC50=93 nM), showing that it acts as an inverse agonist at this receptor [1].
|
|---|---|
| ln Vivo |
While 30 mg/kg deramcicane did not substantially modify dopamine levels at 40-100 min and 160-240 min significantly raised dopamine levels (P<0.05), 3 mg/kg and 10 mg/kg deramcicane did not significantly alter dopamine levels at any time point when compared with basal levels. Deramcicane is a suspected antiserotonergic substance that lessens the effects of serotonergic agonists and the hydrolysis of phosphoinositides generated by 5-HT. Deramcicane and ritanserin share many similarities when it comes to receptor binding. With a high affinity for both 5-HT2A and 5-HT2C receptors, deramcicane functions as an antagonist against both subtypes of receptors and exhibits inverse agonist characteristics at 5-HT2C receptors without directly stimulating the effects of agonists. Numerous animal studies have demonstrated deramcicane's anxiolytic-like properties [2].
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Deramciclane has known human metabolites that include N-Methyl-2-[(1,7,7-trimethyl-2-phenyl-2-bicyclo[2.2.1]heptanyl)oxy]ethanamine. |
| References |
[1]. P?lvim?ki EP, et al. Deramciclane, a putative anxiolytic drug, is a serotonin 5-HT2C receptor inverse agonist but fails to induce 5-HT2C receptor down-regulation. Psychopharmacology (Berl). 1998 Mar;136(2):99-104.
[2]. K??ri?inen TM, et al. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):50-8 |
| Additional Infomation |
Deramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders. Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target. It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.
Drug Indication Investigated for use/treatment in anxiety disorders. Mechanism of Action Deramciclane is a new putative non-benzodiazepine-type anxiolytic compound. It is a selective serotonin 5-HT(2A) and 5-HT(2C) receptor antagonist and has also inverse agonist properties. |
| Molecular Formula |
C20H31NO
|
|---|---|
| Molecular Weight |
301.46624
|
| Exact Mass |
301.241
|
| CAS # |
120444-71-5
|
| Related CAS # |
120444-71-5;120444-72-6 (fumarate);
|
| PubChem CID |
119590
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.01g/cm3
|
| Boiling Point |
375.2ºC at 760mmHg
|
| Flash Point |
110.6ºC
|
| Vapour Pressure |
7.93E-06mmHg at 25°C
|
| Index of Refraction |
1.541
|
| LogP |
4.306
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
399
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CC1(C)[C@]2(C)[C@@](OCCN(C)C)(C3=CC=CC=C3)C[C@@]1([H])CC2
|
| InChi Key |
QOBGWWQAMAPULA-RLLQIKCJSA-N
|
| InChi Code |
InChI=1S/C20H31NO/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16/h6-10,17H,11-15H2,1-5H3/t17-,19-,20+/m1/s1
|
| Chemical Name |
N,N-dimethyl-2-[[(1R,2S,4R)-1,7,7-trimethyl-2-phenyl-2-bicyclo[2.2.1]heptanyl]oxy]ethanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~331.71 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.29 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3171 mL | 16.5854 mL | 33.1708 mL | |
| 5 mM | 0.6634 mL | 3.3171 mL | 6.6342 mL | |
| 10 mM | 0.3317 mL | 1.6585 mL | 3.3171 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
